Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Special Features of Adaptive Immunity01:20

Special Features of Adaptive Immunity

2.7K
The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
2.7K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

82.6K
Overview
82.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.5K
Development of Immunocompetence01:22

Development of Immunocompetence

624
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
624

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unleashing innovative cross-organ fibrosis therapies by harnessing the omics revolution.

JCI insight·2026
Same author

Targeting TNF/TNFR superfamilies in immune-mediated inflammatory diseases.

The Journal of experimental medicine·2024
Same author

Stricturing Crohn's Disease Single-Cell RNA Sequencing Reveals Fibroblast Heterogeneity and Intercellular Interactions.

Gastroenterology·2023
Same author

Stricturing Crohn's disease single-cell RNA sequencing reveals fibroblast heterogeneity and intercellular interactions.

bioRxiv : the preprint server for biology·2023
Same author

Identification of a broadly fibrogenic macrophage subset induced by type 3 inflammation.

Science immunology·2023
Same author

Epithelial-intrinsic defects in TGFβR signaling drive local allergic inflammation manifesting as eosinophilic esophagitis.

Science immunology·2023

Related Experiment Video

Updated: Dec 11, 2025

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.7K

Opinion on Immune Tolerance Therapeutic Development.

Zaher A Radi1, Thomas A Wynn1

  • 1Pfizer Worldwide Research, Development and Medical, 2253Pfizer Inc, Cambridge, MA, USA.

Toxicologic Pathology
|August 21, 2020
PubMed
Summary

Developing immune tolerance therapies aims to restore immune system regulation for autoimmune disorders. Key challenges include selecting disease models, safety assessments, biomarkers, and regulatory guidelines for drug development.

Keywords:
animal efficacy modelsdrug developmentdrug safetyimmune tolerance

More Related Videos

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

6.1K
A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

648

Related Experiment Videos

Last Updated: Dec 11, 2025

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.7K
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

6.1K
A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

648

Area of Science:

  • Immunology and Pharmacology
  • Drug Development and Regulatory Science

Background:

  • Immune tolerance is crucial for preventing autoimmune diseases, characterized by immune unresponsiveness to self-antigens.
  • Loss of immune tolerance leads to autoantibodies, tissue injury, and autoimmune conditions.
  • Emerging immune tolerance therapies aim to restore immune system regulation for treating autoimmune disorders.

Purpose of the Study:

  • To review the significant challenges in developing pharmaceutical drugs that induce immune tolerance.
  • To outline critical steps from preclinical efficacy in animal models to human translation for tolerance therapies.

Main Methods:

  • Discussion of challenges in selecting appropriate animal models for establishing pharmacological efficacy.
  • Review of essential in vitro and in vivo safety assessment strategies.
  • Identification of relevant biomarkers for human safety and therapeutic efficacy.

Main Results:

  • The review highlights the complexity of translating preclinical findings to human applications.
  • It emphasizes the need for robust safety evaluations and predictive biomarkers.
  • Regulatory guidelines are crucial for successful development of immune tolerance therapeutics.

Conclusions:

  • Developing effective immune tolerance therapeutics requires overcoming significant hurdles in preclinical and clinical development.
  • Addressing challenges in model selection, safety, biomarkers, and regulatory pathways is essential for advancing these treatments.